Figure 3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

A–D, Longitudinal assessment of TF predicts ICI benefit in a pan-solid tumor cohort (n = 521; patients in whom rwPFS or rwOS event occurred before the reindex date were excluded where indicated). A, Kaplan–Meier analysis comparing the rwPFS of MR at any timepoint NR (95% CI, NR–NR) vs. nMR at all timepoints 3.93 months (95% CI, 3.33–4.40); n = 513. B, Forest plot for CPH model for rwPFS with a HR of 0.24 (0.19–0.315) for MR vs. nMR (n = 513). C, Kaplan–Meier analysis comparing the rwOS of MR at any timepoint vs. nMR at all timepoints NR (95% CI, NR–NR) vs. 7.166 months (95% CI, 5.73–9.10; n = 520). D, Forest plot for CPH model for rwOS with a HR of 0.28 (0.21, 0.38) for MR vs. nMR (n = 520).